AMSTERDAM, July 20 /PRNewswire/ -- SynCo Bio Partners B.V., the GMP contract manufacturer of biological-based vaccines and therapeutics, today announced that it had significantly expanded the number of clinical and commercial biopharmaceutical batches it is capable of releasing annually, whilst improving regulatory support continuity for its clients, with the addition of a second Qualified Person (QP) to its Quality Affairs team: Raoul Fisser
Raoul joined SynCo’s Quality Affairs team from Astellas Pharma where he worked in Pharmaceutical Development, having previously gained experience in the Quality Assurance Department of the largest manufacturing site of Yamanouchi in Japan. He will now support SynCo’s existing QP Rob Sprenkels, in the release of GMP batches of recombinant protein, polysaccharide and live-microbial-based bulk drug substances and final product. This addition reflects SynCo’s growing client base and the solid business it has established.
‘Raoul is an excellent addition to SynCo’s Quality Affairs team and this expansion demonstrates the continuous growth in both client base and batch production at SynCo since our inception in 2000. Going forward, we look to supporting our clients in GMP production of an even wider range of novel biopharmaceuticals.’ commented Pierre Warffemius, CEO of SynCo Bio Partners.
SynCo’s expansion in batch release capabilities is a positive step in an ever increasingly competitive CMO market and is of special significance in the current global economic downturn. This development will allow SynCo to continue to grow revenues and to increase the number of GMP biopharmaceutical batches it can release each year.
For more information, please visit http://www.syncobiopartners.com
About SynCo Bio Partners B.V.
SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.
Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo ‘s team are committed to exceeding customer expectations taking a truly collaborative approach to manufacturing.
http://www.syncobiopartners.com
SOURCE SynCo Bio Partners B.V.
CONTACT: De Facto Communications, Hilary Latham, +44-207-861-3027,
h.latham@defacto.com; SynCo Bio Partners B.V., Joanne McCudden,
+31-6-5534-8074, J.mccudden@syncobiopartners.com
